In January, as grass pollen counts began their slow climb across German consulting rooms, a new subcutaneous therapy entered the market under the country's TAV registration regime. Grassmuno's arrival barely registered outside specialist allergy circles, yet it capped a genuinely difficult stretch for the Worthing-based company behind it. Allergy Therapeutics had spent the previous two years absorbing supply disruption and a German regulatory overhaul that squeezed sales and forced repeated recourse to shareholder funding. That the company emerged from it with a marketed product, a refinanced balance sheet and guidance for double-digit growth in the year ahead deserves more attention than a single trading update usually gets.

The headline numbers tell a story of steady repair rather than dramatic reversal. Full-year revenue to 30 June 2026 is expected to reach roughly £59.9m, up about 9% on the prior year, with second-half sales accelerating to 12% growth as Spain and a recovering German registered portfolio did the heavy lifting. Cash reserves nearly doubled to £24.2m. None of this happened by accident. It followed a £40m senior secured facility from Hayfin, a specialist private lender, that replaced older shareholder debt and gave the business room to commercialise Grassmuno properly rather than under financial duress.

That financing route is worth dwelling on, because it says something useful about how mid-sized British life sciences companies are actually getting to market. Government rhetoric about a life sciences superpower tends to focus on venture-backed biotech and the flow of early-stage capital. Less attention goes to companies like Allergy Therapeutics, already commercial, already selling across six European markets, but still needing patient capital to survive a regulatory transition and bring a new product through its first full season. Private credit stepped in where public markets, AIM included, offered little. Whatever one thinks of the wider debate about London's capital markets and the drift of listed companies toward overseas exchanges, this is a case where alternative financing did its job and kept a working therapeutic pipeline intact.

That pipeline has a more direct bearing on the NHS than the balance-sheet story might suggest. Allergy prevalence in the UK has risen steadily for decades, and severe reactions place real strain on paediatric and emergency services that are already stretched. Allergen immunotherapy, which aims to retrain the immune system rather than manage symptoms indefinitely, offers a route to reducing that long-term burden rather than simply medicating around it. Allergy Therapeutics' VLP Peanut programme, still early but through a safety-endpoint milestone in December, sits in exactly the space where unmet need is greatest and where a successful domestic developer would matter to UK patients regardless of where the company's shares are listed.

None of this erases the genuine tests still ahead. The FY2027 growth target rests heavily on Grassmuno's first uninterrupted season, and the conclusion of Germany's TAV transition in October will need to go smoothly for that case to hold. Guidance is still guidance, not audited fact, and the new debt facility means the group now carries financing obligations it did not have before. These are the ordinary risks of a company mid-recovery, not signs the story is hollow, and management appears to know exactly what has to happen next.

For NHS leaders and policymakers watching Britain's life sciences sector search for a workable financing model, Allergy Therapeutics offers something closer to a working example than a warning. A company that could easily have folded under supply and regulatory pressure instead found capital, launched a genuinely new therapy and set out a credible path to growth. If the government's life sciences ambitions are to mean anything beyond headline investment figures, they need more companies proving that recovery, and not just early-stage promise, is still possible to finance and deliver from Britain.